Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
al, alive, ANDA, antitrust, appeal, Architect, basal, Bejing, BlackRock, break, Canadian, Caribou, CCSP, CDPSE, CFE, CISA, CISSP, closeout, Cloud, CMDh, CME, CMMC, Cohen, cytogenic, dark, Dhakal, Diego, encryption, Erroneously, escalate, fake, gastroesophageal, GCC, geolocation, GRC, handover, hazard, hosted, hosting, Hudson, IASO, incomplete, incumbent, ingredient, inquiry, intelligence, Interagency, ISSAP, ITGC, Jinyou, Korean, laid, licensee, longest, MBA, melanoma, mentioned, myelodysplastic, nongovernmental, omitted, palsy, parity, PDCO, pen, Pharma, Pratt, RA, realignment, recipient, reversionary, Rowe, San, Sana, sentence, SOC, SOFR, stay, subscribing, template, Tentative, Tongfang, true, unduly, unproven, unrealized, unsafe, web
Removed:
Accountable, AML, Brexit, Centre, Century, CHIP, clinician, continuity, cut, delisted, delisting, desire, distancing, experiencing, fit, formula, furlough, gained, HFCA, innovator, IPO, nonrenewal, Precision, Reauthorization, redeemable, Relief, spiked, strain, supportive, surfaced, Sustainable, twenty, worker, Zhenjiang
Filing tables
Filing exhibits
Associated LEGN transcripts
LEGN similar filings
Filing view
External links
EXHIBIT 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-239478) pertaining to the Share Option Scheme and the 2020 Restricted Shares Plan of Legend Biotech Corporation,
(2) Registration Statement (Form F-3 No.333-257609) of Legend Biotech Corporation, and
(3) Registration Statement (Form F-3 No.333-257625) of Legend Biotech Corporation;
(4) Registration Statement (Form F-3 No.333-272222) of Legend Biotech Corporation;
of our reports dated March 19, 2024, with respect to the consolidated financial statements of Legend Biotech Corporation and the effectiveness of internal control over financial reporting of Legend Biotech Corporation included in this Annual Report (Form 20-F) of Legend Biotech Corporation for the year ended December 31, 2023.
/s/Ernst & Young LLP
Iselin, New Jersey
March 19, 2024